PanK Small-Molecule Modulators for CoA Level Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tools are lacking for investigating the relationship between Coenzyme A (CoA) levels and neurodegeneration, and there is a need for potent modulators of pantothenate kinase (PanK) to address diseases like PKAN and diabetes.
Innovation Solution
Development of small molecule modulators of PanK, including specific compounds that can activate or inhibit PanK activity, to modulate CoA levels and treat associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PanK2 is deleted or inactivated to study CoA levels and neurodegeneration, then the relationship between CoA and neurodegeneration can be investigated, but no effective tools exist to modulate PanK activity for therapeutic purposes
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that can modulate PanK activity. These compounds serve as tools to investigate the relationship between CoA levels and neurodegeneration, while also having therapeutic potential for treating PKAN and diabetes by restoring normal PanK function without requiring genetic manipulation.
2Reliability
If PanK activity is inhibited to reduce CoA levels for treating diabetes, then glucose homeostasis can be normalized, but CoA supply limitation occurs which affects neuronal metabolism and function
Solution Approach 1:
The patent develops tissue-specific PanK modulators that can selectively target different PanK isoforms in different tissues. This allows for localized modulation where PanK activity can be reduced in liver tissue to improve glucose homeostasis while maintaining or protecting PanK activity in neuronal tissue to preserve neuronal metabolism and function.
3Measurement precision
If genetic deletion of Pank1 is performed to study CoA levels, then the impact on oxidative metabolism and glucose homeostasis can be demonstrated, but the model results in early death due to hypoglycemia and reduced fatty acid oxidation
Solution Approach 1:
The patent employs partial modulation of PanK activity using small molecule compounds rather than complete genetic deletion. This partial action allows researchers to study the impact of altered CoA levels on oxidative metabolism and glucose homeostasis without causing the severe hypoglycemia and early death observed in complete Pank1 knockout models, enabling longer-term studies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed compounds effectively modulate PanK activity, stabilizing the enzyme and altering CoA levels, providing therapeutic potential for conditions such as PKAN and diabetes.
Implementation Method 1
The data demonstrate interaction between purified protein and compound that increases the protein resistance to thermal denaturation
Implementation Method 2
Pantothenate Kinase (PanK, EC 2.7.1.33) catalyzes the biochemical conversion of pantothenate (vitamin B5) to phosphopantothenate
Implementation Method 3
CoA is an essential cofactor that functions as a carboxylic acid substrate carrier in various synthetic and oxidative metabolic pathways
Data Source
AI summary
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.